Woman, 53 years of age. Type 2 diabetes and is obese. Patient’s daughter was getting married. She was very motivated to lose weight for the wedding and she did. Her A1C lowered from 7.5% to 6.6%. She cut back on her carbs to <100gm/day, increased her activity and took her metformin regularly. She lost 22 pounds over 6 months. The wedding was 2 months ago and she has gained 6 pounds. That may not seem like much, but it was enough to raise her A1C and open her eyes.

Blandine Lacroix talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 1 of this Exclusive Interview, Blandine Lacroix explains the focus of Novo Nordisk on understanding how to improve the care of obesity in the search for the cure for diabetes.

In this week's Homerun Slides, the safety warnings, precautions, and incorporation of SGLT-2 inhibitors into diabetes treatment.

Insulin resistance in humans: abnormalities in insulin signaling and in the glucose transport effector system Although the key elements of the insulin signaling network have been defined by studies employing molecular and cell biology techniques, a number of studies have focused on translating this knowledge to human studies in a clinical research setting. Insulin resistance in peripheral tissues characterizes obesity and T2DM, and is involved in the pathogenesis of diabetes.

Sometimes it takes a while to find the missing link when it comes to patient care. When insulin was first used in the 1920s, it was viewed as a cure for diabetes. But as hard as we tried using insulin, we never got to good glucose levels. In the late …

New dual drug could be a diabetes breakthrough.

Current study in Lancet showed that patients reduced their A1c levels by 1.55%.

Only GLP-1 receptor agonist for use with mealtime or basal insulin for adults with type 2.

Even though amputation is not a major effect, it is still important to let patients know about it and how to prevent it with proper foot care.

As problems for Tandem continue, and with Johnson & Johnson abandoning the insulin pump market, it’s beginning to dawn on some people that we soon could live in a world with just two insulin pump companies – Medtronic and Insulet.